{
  "documentMetadata": {
    "title": "Gonorrhea: Urethritis, Cervicitis, Proctitis",
    "sourceFile": "Gonorrhea_ Urethritis, Cervicitis, Proctitis.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "50% of patients with urethritis, cervicitis due to N. gonorrhoeae have concomitant C. trachomatis infection or vice versa; hence, treat for both unless NAAT indicates a single pathogen. See updated 2021 CDC guidelines for STD MMWR Recomm Rep 70 (RR-4):1 2021",
        "The following classes of antimicrobials are no longer recommended due to high levels of resistance:",
        "Fluoroquinolones are not recommended for treatment of gonococcal infections. See 2020 CDC gonorrhea guidelines MMWR 69:1911 2020",
        "Oral cephalosporins are also no longer recommended due to high-level resistance (MMWR 61:590, 2012). For cephalosporin resistance in North America, see JAMA 309:163, 2013; JAMA 309:185, 2013.",
        "The CDC no longer recommends dual therapy for gonococcal infections MMWR 69:1911 2020 (European guidelines still recommend dual treatment)",
        "Ceftriaxone 500 mg IM x 1 dose (or if ≥150 kg or 300 lb treat with 1gm IM)",
        "If concomitant C. trachomatis is not excluded treat with Doxycyline 100 bid x 7 days"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Neisseria gonorrhoeae",
        "Chlamydia trachomatis"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Diagnosis"
    },
    {
      "type": "list",
      "items": [
        "Nucleic acid amplification test (NAAT). NAAT FDA-approved for specimens from endocervix, vagina, male urethra, and male/female urine; also useful on pharyngeal and rectal swabs.",
        "Do concomitant NAAT for C. trachomatis."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "strengthOfRecommendation": "Recommended",
        "components": [
          {
            "drug": "Ceftriaxone",
            "dose": "500 mg",
            "route": "IM",
            "duration": "1 dose",
            "notes": "for gonorrhea (or if ≥ 150 kg or 300 lb treat with 1gm IM)"
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "strengthOfRecommendation": "Recommended",
        "components": [
          {
            "drug": "Doxycyline",
            "dose": "100",
            "frequency": "bid",
            "duration": "7 days",
            "notes": "for Chlamydia"
          }
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Alternative Regimens"
      ]
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "strengthOfRecommendation": "Alternative",
        "components": [
          {
            "drug": "Azithromycin",
            "dose": "1gm",
            "notes": "is effective for chlamydia but need 2 gm po for gonorrhea. Two grams are not routinely recommended in the US for monotherapy of gonorrhea due to Gl side-effects, expense and rapid emergence of resistance."
          }
        ]
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "strengthOfRecommendation": "Alternative",
        "components": [
          {
            "drug": "Ceftizoxime",
            "dose": "500 mg",
            "route": "IM"
          },
          {
            "drug": "Cefotaxime",
            "dose": "500 mg",
            "route": "IM",
            "notes": "where available outside the US",
            "connector": "or"
          },
          {
            "drug": "Cefoxitin",
            "dose": "2 gm",
            "route": "IM",
            "connector": "or"
          },
          {
            "drug": "Probenecid",
            "dose": "1 gm",
            "route": "po",
            "connector": "+"
          }
        ],
        "notes": "could substitute for ceftriaxone"
      }
    },
    {
      "type": "drugRegimen",
      "regimenData": {
        "intent": "treatment",
        "strengthOfRecommendation": "Alternative",
        "notes": "Oral cephalosporins are no longer recommended unless ceftriaxone is not available; then consider Cefixime 800 mg po x 1 but with a test of cure (NAAT) roughly 14 days post-treatment."
      }
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Other options (but cure rate for concomitant oro-pharyngeal gonorrhea is lower):"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Alternative",
            "components": [
              {
                "drug": "Spectinomycin",
                "dose": "2 gm",
                "route": "IM",
                "duration": "1 dose"
              }
            ],
            "notes": "Resistance can emerge rapidly."
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Alternative",
            "components": [
              {
                "drug": "Cefixime",
                "dose": "800 mg",
                "route": "PO",
                "duration": "1 dose"
              }
            ]
          }
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Options if patient fails treatment:"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Alternative",
            "components": [
              {
                "drug": "Ceftriaxone",
                "dose": "500 mg",
                "route": "IM",
                "duration": "1 dose"
              }
            ],
            "notes": "+ treat sex partners; NAAT test of cure 1-2 weeks-post treatment."
          }
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Regimens used as salvage therapy or for patients allergic or intolerant to cephalosporins:"
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Alternative",
            "components": [
              {
                "drug": "Gentamicin",
                "dose": "240 mg IM (5 mg/kg if <45 kg)",
                "duration": "1"
              },
              {
                "drug": "Azithromycin",
                "dose": "2 gm po",
                "duration": "1",
                "connector": "+"
              }
            ]
          }
        },
        {
          "type": "drugRegimen",
          "regimenData": {
            "intent": "treatment",
            "strengthOfRecommendation": "Alternative",
            "components": [
              {
                "drug": "Gemifloxacin",
                "dose": "320 mg po",
                "duration": "1"
              },
              {
                "drug": "Azithromycin",
                "dose": "2 gm po",
                "duration": "1",
                "connector": "+"
              }
            ]
          }
        },
        {
          "type": "paragraph",
          "text": "Results: Microbiologic cure in 100% of those given Gentamicin + Azithromycin and 98% of those given Gemifloxacin + Azithromycin. Responses included 25 patients with pharyngeal GC and 6 with rectal GC: Clin Infect Dis 59:1092, 2014."
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Due to rapid emerging resistance of many organisms to macrolides with routine use, routine dual therapy of gonorrhea no longer recommended by CDC: MMWR 69:1911 2020",
        "See CDC report on 2018 STI resistance patterns"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "Screen all patients with gonococcal infections for syphilis and HIV.",
        "Partners can be treated with Cefixime 800 mg po +/- Doxycycline 100 mg bid x 7 days if permitted by local laws",
        "Experts recommend re-testing for C. trachomatis 3 months after treatment owing to frequent re-infection.",
        "If pregnant and treating for Chlamydia, use Azithromycin 1gm po instead of doxycycline.",
        "2020 CDC Guidelines for treatment of gonorrhea: MMWR 69:1911 2020 and updated 2021 CDC Guidelines for STD MMWR Recomm Rep 70 (RR-4):1 2021",
        "2020 European Guidelines for treatment of gonorrhea: Int J STD & AIDS 2020",
        "UK case report of high-level GC resistance to Azithromycin (MIC >512 µg/mL) with resistance to Ceftriaxone (Euro Surveill 23(27), 2018) that was treated with Ertapenem.",
        "Both US and European guidelines significantly revised in 2020",
        "European guidelines (Int J STD & AIDS 2020) recommend Ceftriaxone 1 gm IM + 2 gm Azithromycin OR Ceftriaxone 1gm IM with test of cure (US guidelines do not recommend test of cure except for pharyngeal gonorrhea).",
        "Randomized control trials show Doxycycline 100 bid x 7 days superior to Azithromycin 2 gm x1 in MSM with rectal Chlamydia CID [Clin Inf Dis. 73: 824, 2021, NEJM 384:2418, 2021]",
        "Rectum may the only site of Chlamydia infection and may not be associated with a history of anal intercourse Clin Infect Dis 74:S112 2022",
        "Doxycycline 100 bid x 7 days superior to Azithromycin 2 gm x1 in men with symptomatic urogenital symptoms Clin Infect Dis 74:S112 2022",
        "Review of evidence for CDC guidelines: Clin Infect Dis 74:S95 2022 (Gonorrhea) and Clin Infect Dis 74:S112 2022 (Chlamydia)"
      ]
    }
  ]
}